esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study
Published 3 years ago • 2.3K plays • Length 3:05Download video MP4
Download video MP3
Similar videos
-
2:27
esmo 2020 highlights on neoadjuvant ici in early tnbc: the impassion031 study
-
2:58
#esmo22 highlights on sacituzumab govitecan in hr /her2- metastatic breast cancer: tropics-02
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
2:35
esmo 2020 highlights on 1st line durvalumab and tremelimumab for mpdac: the pa.7 study
-
2:26
esmo 2020 highlights on alpelisib plus fulvestrant for hr /her2– abc: the solar-1 study
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
2:39
esmo 2020 highlights on 1st line lorlatinib for alk nsclc: the crown study
-
2:45
esmo 2020 highlights on neoadjuvant mfolfirinox for t3-4 rectal cancer: the prodige 23 study
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
2:05
esmo 2020 highlights on nivolumab cabozantinib as 1st line therapy for arcc: the checkmate 9er study
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc
-
1:41
esmo breast 2021 highlights
-
3:07
esmo 2020 highlights on blocking pi3k/akt signalling pathway in mcrpc: the ipatential150 study
-
3:50
breast cancer at esmo 2020: impassion131, solar-1, pallas and more
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
0:18
achieving the esmo vision 2020, and looking beyond